Xylo Bio

Really enjoying participating in the One Mind Accelerator this week! Amazing to be surrounded by both pioneers and veterans in #biotech and #nuerotech in the heart of Silicon Valley. 👏

✈ From East to West: After a successful Neuroscience Partnering Summit in Boston, Xylo Bio is heading to #SanFrancisco next week to join the 2025 One Mind Accelerator! We’re honored to be one of just 10-12 startups selected from over 100+ applicants for this highly competitive program, which supports early-stage mental health startups with the network, mentorship, and funding to scale transformative solutions. 🧪 At Xylo Bio, we’re pioneering the next generation of neuroplastogens to transform mental health and neurological disease treatment. Through the One Mind Accelerator, we’ll collaborate with visionary founders, leading experts, and industry pioneers, gaining the tools to accelerate our impact and drive meaningful change. Thank you to One Mind and its network of mentors, advisors, and partners for this incredible opportunity! We’re excited to learn, grow, and innovate alongside an inspiring cohort. 🤝 🧪 Joshua Ismin (CEO), 💊 Sam Banister (CSO), and Samantha Tabone (Director of Business Development) will be in the Bay Area next week – reach out if you’d like to connect! #XyloBio #OneMindAccelerator #Biotech #DrugDevelopment #Neuroscience #MentalHealth #Startups

🧠 Xylo Bio is at the Neuroscience Innovation Pharma Partnering Summit! We’re excited to join this focused gathering of neuroscience leaders and connect with partners, investors, and experts shaping the future of CNS drug development. 📌 Don't miss our Co-founder & CSO, 💊 Sam Banister, presenting: "Development of Non-Hallucinogenic Neuroplastogens Targeting 5-HT2A for the Treatment of Psychiatric Disorders" ‣ Wednesday, Feb 19 | 9:20 AM He’ll dive into Xylo's development of neuroplastogens - targeted neurotherapeutics designed to rewire neural circuits and restore brain function without hallucinatory effects. Our director of business development, Samantha Tabone, is also attending and available for meetings. If you’re in Boston or Cambridge, reach out to Sam and Sam to explore how we can collaborate to bring innovative CNS therapies to patients in need! #XyloBio #Neuroscience #Biotech #CNS #DrugDevelopment #Innovation #Neurotherapeutics #MentalHealth

📣 We’re Hiring: VP of R&D at Xylo Bio! 🧪 At Xylo Bio, we’re pioneering the next generation of neuroplastogens to transform mental health and neurological disease treatment. As we advance our discovery platform and move toward the clinic, we’re looking for a VP of Research & Development to lead our R&D efforts and help shape the future of neuropharmacology. What You’ll Do: • Drive preclinical research from discovery through IND-enabling studies. • Oversee medicinal chemistry, pharmacology, and translational research. • Collaborate with a world-class team of scientists and advisors. • Lead the development of novel, non-hallucinogenic neuroplastogens. This is a unique opportunity to lead cutting-edge CNS drug development and bring breakthrough science to patients. If you're a hands-on leader with deep expertise in CNS drug discovery and development, we’d love to hear from you! Know someone who’d be a great fit? Tag them or share this post! 📌 Learn more & apply here: https://lnkd.in/gXmCjpxy #XyloBio #Hiring #Biotech #DrugDevelopment #Neuroscience #RnD #Leadership 💊 Sam Banister 🧪 Joshua Ismin Samantha Tabone ⚗️ William Jorgensen Krista Licata Alan Kozikowski Alex Kwan Graham Pechenik Dr. Jianmin Duan Ryan Bethencourt Eric J. Nestler, MD, PhD John Krystal Donald Gehlert, Ph.D. Bradley Joblin Elaine Stead Margarita Chavez Steve Burnell Mike Lamprecht Shelby Clark Brom Rector, CFA Ken Belotsky, Main Sequence Tenmiles Lionheart Ventures FocalPoint Partners Negev Capital Possible Ventures

En route to Boston. 💊 Sam Banister and I are going to be here all week and attending the Neuroscience Pharma Innovation Partnering Summit on behalf of Xylo Bio. Xylo Bio is an XEIA Venture Partners portfolio company developing targeted neurotherapeutics for psychiatric and neurological disorders. We'll be boots on the ground talking to investors, founders, pharma partners and other biotech executives enthusiastic about neuro this week around downtown Boston and Cambridge. Send me a note if you want to connect and fit in a quick visit!

I'm looking forward to attending the Neuroscience Innovation Pharma Partnering Summit in Boston next week with 💊 Sam Banister on behalf of Xylo Bio. Sam and I will be in Boston taking meetings all of next week as well. We're excited to share more about Xylo's progress towards the clinic. Let me know if you want to grab coffee and chat all things neuropharmacology with Sam and I.

📣 We’re hiring: Medicinal Chemist – Sydney, AUS At Xylo Bio, we are pioneering next-generation neuroplastogens to develop transformative treatments for mental health and neurological disorders. We are seeking a Medicinal Chemist to join our discovery team in Sydney, contributing to the advancement of CNS drug development. 💊 Key Responsibilities: - Design and synthesize novel small molecules targeting neuroplasticity. - Support IP development and contribute to scientific publications. - Collaborate with chemists, biologists, and external partners. - Advance lead candidates toward clinical translation. - Work in a fast-paced, collaborative environment at the forefront of neurotherapeutics. 🥼 About You: - Ph.D. in Chemistry (or equivalent industry experience). - Expertise in small molecule synthesis, medicinal chemistry, and CNS drug discovery. - A passion for innovation in neurotherapeutics. 🚀 Join our team and help shape the future of CNS drug discovery, developing novel therapies that have the potential to change lives. 📌 Learn more & apply here: https://lnkd.in/eyisSwDW If you or someone in your network would be a great fit, we’d love to connect! #Hiring #Biotech #MedicinalChemistry #DrugDevelopment #Neuroscience #Chemistry, 💊 Sam Banister, ⚗️ William Jorgensen, Krista Licata, Jin Tan, Lachlan Whish, 🧪 Joshua Ismin, Joanna Hare, Nick Everett, Bradley Joblin, Dr. Jianmin Duan, Dilara Bahceci

The Xylo Bio team is driving innovation at #JPM2025, sharing our mission to transform CNS health with targeted neurotherapeutics. We're energized by conversations with leaders who share our vision for advancing innovative treatments and transforming lives. Let’s keep the momentum going - connect with us to explore how we can reshape neurotherapeutics together! 🧪 Joshua Ismin 💊 Sam Banister Samantha Tabone Tenmile Main Sequence #XYLO #Biotech #Neurotherapeutics #DrugDiscovery #CNSHealth #MentalHealth

We’re grateful for the continued support from Main Sequence as we enter this exciting new chapter as Xylo Bio. With our advanced computational drug discovery platform and focus on neuroplastogens, we’re committed to developing targeted therapies that transform the treatment of psychiatric and neurological disorders. Thank you for believing in our mission to improve lives through innovation! #Biotech #Neurotherapeutics #Innovation

The Xylo Bio team is thrilled to be at #JPM2025! As a cutting-edge #neuroscience biotech company, we’re dedicated to transforming lives with targeted neurotherapeutics that rewire neural circuits and restore brain function. We’re excited to connect with partners and investors who share our vision for advancing innovative treatments and making a real impact. If you’re at the J.P. Morgan Health Care Conference, don’t miss the chance to meet with 🧪 Joshua Ismin, 💊 Sam Banister, and Samantha Tabone to explore how we can collaborate to advance the next generation of neurotherapeutics! #Xylo #biotech #CNS #neurotherapeutics #neuroplastogens